Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the ...
The HER2CLIMB-05 trial is a randomized, double blind, placebo-controlled, pivotal Phase 3 study evaluating the efficacy and safety of TUKYSA compared to placebo, both in combination with trastuzumab ...
LITFULO significantly improved facial and total body repigmentation at Week 52 compared to placebo, with continuous improvement starting at Week 24, supporting planned regulatory filings for a ...
NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the company’s common stock, payable December 7, 2026, ...
At Pfizer, interviews are a significant component of our hiring assessment process. The purpose of an interview is to get to know you better as a person, give you an opportunity to share your amazing ...
At Pfizer, we’re eager to connect with you. Follow Pfizer and our CEO Albert Bourla’s Influencer posts on LinkedIn and Twitter. Get your Pfizer news in small bits by following @Pfizer and ...
(NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-t ...
Data across 45 abstracts will highlight new evidence for established medicines, including PADCEV and TALZENNA, and promising late-stage pipeline candidates such as atirmociclib and tivunatamig ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results